secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0000950170-23-029646
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints Ira Duarte as CFO effective June 16, 2023
---------------------------------------------------------------------

- Ira Duarte named CFO; previously CFO of Veloxis Pharmaceuticals and held finance roles at BioDelivery Sciences, Chiesi USA, and Ernst & Young.
- Compensation includes $500K base salary, $250K target bonus (pro-rated for 2023), and inducement award of options for 800K shares, 50K RSUs, and performance options for up to 500K shares.
- Inducement award granted outside 2007 Plan with four-year vesting for options and RSUs; performance options vest based on stock price goals.
- Duarte also holds a board seat at TerrAscend Corp. since December 2022 and is a CPA with a BS in Accounting from Florida Atlantic University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/0000950170-23-029646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/hrtx-20230616.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer